• FDA Reviews Application for Keytruda in Mediastinal B-cell Lymphoma
  • 5-Year Survival Rates Promising for MTLC Patients Treated with Adcetris in Phase 1 Trial
  • Is My History of Cancer a Disability in the Workplace?
  • 40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta
  • Immune Response to Reactive Herpes Virus Tied to Graft-versus-host Disease in Transplant Patients in Study
  • Aptevo to Launch Phase 2 Trial of Therapy Candidate for Peripheral T-cell Lymphoma
  • Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants
  • Polatuzumab Vedotin Addition Makes Stark Difference for DLBCL Patients, Studies Show
  • How I Celebrate My Cancerversary
  • TRPH-222 Shows Significant Anti-tumor Activity in Lymphoma Preclinical Models
  • Survey Helps Doctors Better Understand Therapy Choices by Chronic Lymphocytic Leukemia Patients
  • Eureka Technologies Receives FDA’s OK to Move T-cell Therapy into Clinical Trials